The project aims to address disparity in access to treatments and prioritize populations and regions that bear the greatest burden of the hereditary blood disease, Novartis said.
Around 300,000 people are born with the condition annually. Sub-Saharan Africa is particularly badly affected by SCD, which reduces the ability of red blood cells to transport oxygen and can be fatal.
By Reuters Staff
Posted on
Previous Article
« Clever trial design gets patients back on statins: the SAMSON trial Next Article
Adherent-invasive E. coli metabolism drives inflammation in Crohn’s disease »
« Clever trial design gets patients back on statins: the SAMSON trial Next Article
Adherent-invasive E. coli metabolism drives inflammation in Crohn’s disease »
Related Articles
February 3, 2022
Support for fourth COVID-19 jab in blood-cancer patients
June 15, 2023
Long-term success for CD19 CAR T-cell therapy in CLL
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com